drugset / Trial / NCT03023449

Diffuse Optical Monitoring With Inhaled Nitric Oxide

NCT03023449

Phase 2 Active not recruiting 40 enrolled Steven Messe Mallinckrodt · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

This study is a non-randomized, Phase 2 clinical trial designed to measure the cerebral blood flow (CBF) response to inhaled nitric oxide in acute ischemic stroke patients and healthy subjects. The monitoring is a 35 minute session during which cerebral hemodynamics will be monitored with both diffuse correlation spectroscopy (DCS) and transcranial doppler ultrasonography (TCD) while blood pressure, heart rate, cardiac output, respiratory rate, end oxygen saturation, and inhaled nitric oxide (NO)/nitrogen dioxide (NO2) concentration, are continuously monitored.

Timeline

Start
2017-04-04
Primary completion
2021-03-21
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified Inhaled

Indications